Catalyst Trusteeship Limited, acting as Debenture Trustee for API Holdings Limited, has announced the full release of a pledge on 7,94,69,696 equity shares of Thyrocare Technologies Ltd. This release follows the complete repayment and redemption of the Non-Convertible Debentures. The pledge was originally created by Docon Technologies Private Limited.
Pledge Release on Thyrocare Shares
Catalyst Trusteeship Limited, in its capacity as Debenture Trustee for the Debenture Holders of API Holdings Limited, has officially confirmed the release of a pledge on a substantial block of equity shares in Thyrocare Technologies Ltd. The total number of shares affected by this release is 7,94,69,696, representing 49.93% of the total share capital. This action signifies a significant shift in the encumbrance status of these shares.
Transaction Details
The pledge was fully released on August 17, 2026, subsequent to the complete repayment and redemption of the Non-Convertible Debentures. The shares were originally pledged by Docon Technologies Private Limited. Prior to this release, these 7,94,69,696 shares were held under encumbrance, accounting for 49.93% of the total share capital and 49.78% of the diluted share capital of Thyrocare Technologies. The total equity share capital of the Target Company remains 15,91,65,315 shares, with a face value of ₹10 each.
Source: BSE
